Effect of hyperprolactinemia and 2-BR-alpha-ergocryptine on neuroendocrine mechanism(s) for gonadotropin control.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D002369:Castration; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism; D006062:Gonadotropins / Q000378:metabolism*; D007033:Hypothalamus, Middle / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000378:metabolism; D009490:Neurosecretory Systems / Q000187:drug effects*; D010903:Pituitary Gland, Anterior; D010911:Pituitary Neoplasms / Q000378:metabolism; D011388:Prolactin / Q000097:blood*; D051381:Rats; D012737:Sex Factors
D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone